Original Article
Clarithromycin (CAM) susceptibility may influence the prognosis and severity of MabC lung disease. [12] [13] [14] [15] However, drug susceptibility testing (DST) of MAA isolates from patients is currently not well documented, but it may predict outcomes in patients with MAA lung disease. [13, 15] This study aimed to evaluate the in vitro drug susceptibility of several antibiotics and to assess the influence of in vitro drug susceptibility of pathogens on MAA lung disease outcomes.
mEthodS

Study design
In this retrospective, single-institution study, files from all consecutive patients referred to National Hospital Organization Kinki Chuo Chest Medical Center, a 385-bed center in Southern Osaka that specializes in pulmonary disease, from January 1, 2010, to December 31, 2014 were reviewed. Patients with MabC lung disease were included if they met the American Thoracic Society (ATS) diagnostic criteria: presence of at least two positive sputum cultures or one bronchoalveolar lavage culture or one lung tissue biopsy specimen culture positive for MabC, along with pulmonary symptoms and chest computed tomography (CT) findings. [16] In addition, patients were included if their isolates were available (in storage) and if they were followed up at least for 1 year until January 2015. This study was approved by the Ethics Committee of Kinki Chuo Chest Medical Center (No. 502, date of approval: July 25, 2015) . Informed consent was waived because of the retrospective nature of the study.
Data collection
Information on patient history was obtained at admission or during an outpatient visit. Height and weight were measured. Data on comorbidities and the course of antinontuberculous mycobacteria (NTM) treatment were collected from the medical records. Patients were diagnosed with MAA of sputum isolates which were identified by hsp65, rpoB, and erm (41). [17] Patients received combination antibiotic therapy as recommended by the ATS and Infectious Diseases Society of America. In addition, patients were diagnosed with NTM coinfection if NTM species other than the MabC was isolated at least twice.
Disease progression was determined in the time interval between the time of making the diagnosis and the 1-year follow-up. After 12 months of treatment, sputum culture conversion or relapse was periodically assessed. Sputum culture negative conversion was defined as two consecutive negative cultures within 3 months after therapy for 12 months. If a patient could not expectorate sputum even after sputum induction, sputum conversion from positive to negative was considered to have occurred. Relapse was defined when there was at least one positive sputum culture during the study period and the positive sputum culture became negative. The enrolled patients were classified into three groups: Group A (favorable response), which comprised patients with MAA lung disease in the negative conversion group; Group B (unfavorable response), which comprised patients with persistently positive cultures or negative conversion with relapse; and Group C (no treatment intervention), which comprised patients with follow-up for at least 1 year without any antibiotics.
Microbiological examination
We performed DST in vitro before the treatment. The interpretative breakpoints used were those recommended by the Clinical and Laboratory Standards Institute (CLSI). [18] The minimal inhibitory concentration (MIC) was defined as the lowest concentration of drug that inhibited visible growth. MICs in CAM were determined in cation-adjusted Mueller-Hinton medium using the broth microdilution method (pH 7.35-7.40). Plates were evaluated after 3 days and then incubated for 14 days to obtain a final reading to ensure the detection of inducible resistance. The MIC of CAM was determined on day 3 and day 14 after incubation; MAA isolates were considered susceptible (MIC ≤2 µg/mL on day 3 and day 14) or resistant (MIC ≥8 µg/mL on day 3). Susceptibilities to other antibiotics (kanamycin [KM], amikacin [AMK], linezolid [LZD], and imipenem [IPM]) were also evaluated according to previous reports. [14, 19] The breakpoint of sitafloxacin hydrate (STFX) was complained with it of moxifloxacin and ciprofloxacin for RGM in CLSI. [18] 
Genetic analyses
To extract DNA, a loopful of colonies of each strain was used, and the extracted DNA was suspended in 300 ml 16 Tris-ethylenediaminetetraacetic acid buffer and boiled for 10 min. The polymerase chain reaction (PCR) cycling conditions were as follows: initial denaturation at 95°C for 2 min; 35 cycles of denaturation at 95°C for 1 min, annealing at 62°C for 1 min, and extension at 72°C for 1.5 min, and a final extension at 72°C for 10 min. Genetic analyses, such as the presence of erm (41) or 23S rRNA gene (rrl) mutations, were performed by PCR sequencing as previously described. [17, 20, 21] 
Statistical analysis
Categorical variables were analyzed using the Chi-square or Fisher's exact test. Continuous variables were analyzed using the Mann-Whitney U-test or t-test. All P values are two-sided. P < 0.05 indicates statistical significance. Statistical analyses were performed using the JMP statistical software (12 th version, SAS Institute Inc., Cary, NC, USA). Proportions and medians were used to describe demographic, clinical, and radiographic characteristics.
rESultS
Clinical information of patients
Among 79 patients with at least one respiratory sputum culture containing an MabC isolate, 38 had the MAA isolate, and in 3 patients, the isolate could not be confirmed because their isolate cultures did not develop. None were identified as having M. abscessus subsp. bolletii or MAA/ MAM mixed lung disease. Of the 38 patients with at least one respiratory sputum culture of the MAA isolate, there were 30 with MAA lung disease who met ATS diagnostic criteria [16] [ Figure 1 ]. Table 3 ]. Two isolates of the C28 sequevar for erm (41) and one isolate of the T28 sequevar in Group A exhibited CAM susceptibility on day 14. In contrast, two isolates of the rrl gene were observed only in Group B. There was not significantly relationship between susceptibility to other antibiotics (KM, AMK, STFX, LZD, and IPM) and biological outcomes [ Table 3 ].
One of the seven patients had the isolate of the C28 sequevar, and no patient in Group C had the isolate with rrl mutation [ Table 3 ].
dIScuSSIon
This study demonstrated two important findings. First, in vitro DST of MAA isolates greatly affects negative conversion in patients with MAA lung disease. Our findings indicated that CAM susceptibility on day 14 is of particular importance. No clear relationships were shown indicating whether the other drugs affected negative conversion. Second, patients with MAA lung disease having the C28 sequevar in their isolate tended to exhibit negative conversion.
MAA is known to have poorer treatment outcome because of drug resistance to many antibiotics even among other types of nontuberculous mycobacteria. Susceptibility to CAM, AMK, and IPM is usually maintained. [22] It has been proposed that rather than in vitro DST with a standard culture period of 3 days, CAM should be cultured for 14 days because of inducible resistance due to the erm (41) gene. [23] The guidelines [16] recommend selecting the treatment regimen based on in vitro DST of MAA. Our investigation of the correlative relationships between susceptibility to several antibiotics with bacterial negative conversion in patients with MAA lung disease demonstrated that CAM susceptibility on day 14 strongly influenced negative conversion. This result was consistent with the results of a single-institution study conducted in South Korea. [15] We performed susceptibility tests for other drugs and investigated the correlation between negative conversion in the present study. We were unable to prove any clear correlative relationships showing susceptibility to drugs other than CAM. These findings suggest that CAM is a key drug for treating MAA lung disease. Further studies are needed to identify an appropriate regimen that achieves a good balance between treatment success and toxicities in patients with MAA lung disease.
Although we observed a tendency for negative conversion of the C28 sequevar in the isolate of MAA lung disease, this finding was not statistically significant. Park et al. indicated that the C28 sequevar in the MAA isolate affects bacterial negative conversion in MAA lung disease. [15] The lack of a significant difference noted in the present study might have been due to the small sample size. Interestingly, the C28 sequevar accounted for many patients undergoing follow-up observations due to a lack of progression and for patients who did not meet the diagnostic criteria. This suggested that MAA lung disease with the isolate of the C28 sequevar does not cause rapid progression and that treatment intervention might be unnecessary.
Current recommendations for MAA lung disease treatment are based on case series studies with no comparison cases or on individual experience. [8, 13, 24] Harada et al. reported the DST of the MabC isolate in the registry study, [14] but they did not evaluate how in vitro DST of MAA affects the induction of sputum conversion, and few reports have evaluated the clinical effects of various drugs. [25] The present study investigated the usefulness of DST of the MAA isolate and found that susceptibility to CAM on day 14 greatly affected sputum conversion.
DST results for CAM susceptibility on day 3 indicated more resistance than those reported by Park et al. [15] and Koh [13] in Korea. There are several explanations for this difference in CAM susceptibility on day 3 and the rate of negative conversion in MAA lung disease. There is a likelihood of the influence of regional differences in the same Asian area and the mechanism of resistant to CAM (not only inducible resistance but also natural resistance).
The importance of CAM susceptibility is similar in patients with M. avium complex lung disease, indicating that CAM susceptibility is related to the treatment response rate. [26] No effective treatment regimen has been established for CAM-resistant MAC lung disease, and the prognosis is poor. [27] Moreover, an inappropriate regimen can induce CAM resistance. [27] Many patients with MAA lung disease have a history of receiving chemotherapy including CAM for MAC lung disease. [28] Having already underwent treatment for MAC lung disease, which is a common comorbidity, may affect the results of DST of MAA lung disease and ultimately affect negative conversion in patients MAA lung disease.
The limitations of this study were the fact that it was a single-institution study with a small sample size; further, it was a retrospective cohort study. The treatment regimens were decided by physicians. Oral agents (CAM, EB, RFP, and STFX) as the initial treatment were received because some patients refused the admission. In terms of sputum conversion, we could not divide our analysis according to cases of reinfection and continued infection. Although parenteral agents such as AMK and IPM are considered necessary when treating patients with pulmonary MAA disease, current recommended regimens are limited by factors such as toxicity.
In the present study, LZD and KM were rarely used to treat MAA lung disease because of the moderate-to-severe side effects in Japan. [14] In the future, multicenter prospective studies with a unified regimen need to be conducted to investigate this research topic further.
concluSIonS
In vitro DST of MAA isolates greatly affects sputum conversion. This study revealed that CAM susceptibility on 
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